von Hofe E, Papamichail M, Peoples GE. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence. Ann
美国食品及药品管理局(FDA)一个顾问委员会全票通过了允许默沙东公司(Merck)宫颈癌疫苗上市的建议,这意味着人类抗癌战争即将进入一个划时代的新阶段。除了HPV外,还有不少疫苗进入临床,有的虽然鉴于各国巨额的临床试验费用没有获得类似FDA的批...
Despite additional trastuzumab emtansine (T-DM1) in the adjuvant setting, a significant number of patients with residual disease still develop recurrence. H2NVAC is a multi-epitope T helper cell-activating peptide vaccine that is composed of 4 degenerate HER2-derived HLA-DR epitopes admixed with ...
英文名称:HER2 multi peptide vaccine candidateHER2 multi peptide vaccine candidate is available 3 times 来自 Adi labs,中文名称:HER2多肽疫苗候选株HER2多肽疫苗候选株可用3,产品货号:HER2-MP3,HER2多肽疫苗候选HER2多肽疫苗候
A. The development and use of the E75 (HER2 369–377) peptide vaccine. Future Oncol. 12, 1321–1329 (2016). Article CAS Google Scholar Disis, M. L. et al. Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein–based vaccine. J. ...
HER2/neu Vaccine Tested in Metastatic Breast Cancer+ Y) |1 Q; e0 }) |4 L8 N1 W6 y+ z ...
Maglakelidze M, Ryspayeva DE, Andric Z, Petrovic Z, Bulat I, Nikolic I, et al. HERIZON: a phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2-overexpressing metastatic or advanced gastric/GEJ adenocarcinoma—ove...
The largest part of the literature data about anti-HER2 vaccination strategies concerns vaccines based on peptides derived from this tumor antigen. Numerous clinical trials have been conducted using various peptide vaccine preparations (Table2). Some of them have been completed, while others are curre...
Taken together the data presented in this report strongly suggest that peptide HER2(776–788) represents a candidate helper epitope to be included in vaccine preparation consisting of HER-2/neu peptides presented by MHC class I and class II molecules. With such formulations vaccine-induced HER-2...
2、Clifton, G. T., Peoples, G. E., & Mittendorf, E. A. (2016). The development and use of the E75 (HER2 369–377) peptide vaccine. Future Oncology, 12(11), 1321–1329. doi:10.2217/fon-2015-0054